<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689572</url>
  </required_header>
  <id_info>
    <org_study_id>13419</org_study_id>
    <secondary_id>1R01DA021776-01A1</secondary_id>
    <nct_id>NCT00689572</nct_id>
  </id_info>
  <brief_title>New Medication Treatment for Stimulant Dependence</brief_title>
  <official_title>New Medication Treatment for Stimulant Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of ondansetron compared with placebo in the treatment
      of cocaine dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to conduct a 9 week randomized, controlled clinical trial to evaluate the efficacy
      of ondansetron 4 mg twice daily compared with placebo (total N = 100/group Ã— 2 groups = 200
      individuals randomized, 400 total subjects will be consented), provided as an adjunct to
      manual-driven, structured CBT + BBCET in the treatment of cocaine dependence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>increase in cocaine free days (abstinent)assessed by self-reported use and urine analysis for benzoylecgonine</measure>
    <time_frame>Throughout the study</time_frame>
    <description>Cocaine timeline follow-back, QFI, substance use inventory, urine benzoylecgonine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease cocaine craving,and improvement in general well-being, social function, quality of life.</measure>
    <time_frame>Throughout the study</time_frame>
    <description>increased scores in the following assessments: BSCS, CCQ-NOW, CGI, BSI, SFQ, Q-LES-Q, medication compliance (pill count)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy</description>
    <arm_group_label>Ondansetron</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females who have given written informed consent.

          -  Ages 18 years and above and, must weigh at least 40 Kg and no more than 140 Kg.

          -  Good physical health as determined by a complete physical examination, an EKG within
             normal limits, and laboratory screening tests within acceptable parameters.

          -  Current DSM-IV diagnosis of cocaine dependence.

          -  At least one positive urine drug screen for cocaine at screen or baseline prior to
             randomization.

          -  The pregnancy test for females at intake must be negative.

          -  Literacy in English and ability to read, understand, and complete the ratings scales
             and questionnaires accurately, follow instructions, and make use of the behavioral
             treatments.

          -  Answered an advertisement in the newspaper/radio/television, and expressing a wish to
             stop using cocaine.

          -  Willing to participate in behavioral treatments for cocaine dependence.

        Exclusion Criteria:

        Please contact site for additional information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nassima Ait-Daoud Tiouririne, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Center for Addiction Research and Education</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Addiction Research and Education</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.medicine.virginia.edu/clinical/departments/psychiatry/sections/neurobiologicalstudies/uvacare</url>
    <description>(UVA CARE Website)</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Nassima Ait-Daoud Tiouririne</investigator_full_name>
    <investigator_title>Associate Professor, Director of UVA Center for Addiction Research and Education</investigator_title>
  </responsible_party>
  <keyword>cocaine dependence</keyword>
  <keyword>cocaine abuse</keyword>
  <keyword>cocaine</keyword>
  <keyword>crack</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Central Nervous System Stimulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

